Radioimmunotherapy for Malignant Mesothelioma Targeting C-ERC/Mesothelin

Area of Science:

• Oncology
• Immunotherapy
• Radiopharmaceutical therapy

Background:

• Malignant mesothelioma has a poor prognosis and limited treatment options.
• C-ERC/mesothelin is highly expressed in mesothelioma, making it a potential therapeutic target.
• Radioimmunotherapy (RIT) offers a targeted approach for cancer treatment.

Purpose of the Study:

• To evaluate the therapeutic potential of the radiolabeled anti-C-ERC/mesothelin antibody, mAb 22A31.
• To assess the specific binding and biodistribution of mAb 22A31 in mesothelioma models.
• To determine the efficacy of 90Y-labeled mAb 22A31 in preclinical mesothelioma models.

Main Methods:

• Western blotting to assess C-ERC/mesothelin expression in mesothelioma cell lines.
• In vitro binding assays using 125I-labeled mAb 22A31.
• In vivo biodistribution studies with 111In-labeled mAb 22A31 in tumor-bearing mice.
• Therapeutic efficacy evaluation of 90Y-labeled mAb 22A31 in subcutaneous and pleural mesothelioma models.

Main Results:

• mAb 22A31 demonstrated specific binding to mesothelioma cells based on C-ERC/mesothelin expression levels.
• 111In-labeled mAb 22A31 showed tumor accumulation with minimal off-target uptake in normal tissues.
• 90Y-labeled mAb 22A31 significantly inhibited subcutaneous tumor growth and improved survival in a pleural dissemination model.

Conclusions:

• Radiolabeled mAb 22A31 effectively targets C-ERC/mesothelin and exhibits significant therapeutic efficacy in mesothelioma models.
• 90Y-labeled mAb 22A31 represents a promising RIT agent for mesothelioma.
• These findings support further development of C-ERC/mesothelin-targeted therapies for malignant mesothelioma.